REGENXBIO's Hunter syndrome gene therapy RGX-121 receives CRL as FDA questions trial design and biomarker endpoint
The FDA cited concerns over eligibility criteria, external controls and the CSF heparan sulfate surrogate endpoint, weeks before approving Denali's AVLAYAH for the same disease
